Shelter Pharma Limited held its 19th Annual General Meeting on September 29, 2026, in Himmatnagar, Gujarat. Shareholders adopted the audited standalone financial statements for the year ended March 31, 2026.

The company also approved several material related party transactions for the upcoming fiscal year. These include dealings with Gandhi Brothers, Shelter Pharmacy Pvt Ltd, and Al Nasheet Global Business Pvt Ltd. Additionally, the board regularized the appointment of a new independent director.

Key resolutions passed

The meeting addressed both ordinary and special business items as outlined in the notice dated September 1, 2026. The following resolutions were placed for voting:

• Adoption of Financials: Consideration and adoption of audited standalone financial statements for FY26 along with Board and Auditor reports.
• Director Appointment: Appointment of Parvezbanu Mohamed Rafiq Idariya as a Non-Executive Director liable to retire by rotation.
• Related Party Transactions: Ratification of transactions entered during FY26 and approval of material transactions with three specific entities for FY27.
• Independent Director Regularization: Regularization of Vinita Shivraj Gadhavi as a Non-Executive Independent Director via a Special Resolution.

Voting and compliance details

The proceedings were conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. E-voting facilities were provided through Bigshare Services Pvt. Ltd. to ensure broad shareholder participation. Members who did not vote remotely could cast their votes via ballot papers at the venue.

Murtuza Mandorwala, a practicing company secretary, served as the scrutinizer for the voting process. The combined results of remote e-voting and physical polling were scheduled for announcement within two working days. These results will be uploaded on the company’s website and the BSE portal.

Governance updates

Mustaqim Nisar Ahmed Sabugar, Chairman and Managing Director, chaired the meeting. He welcomed members and introduced the board. The meeting confirmed the presence of requisite quorum before commencing formal proceedings. No questions were raised by shareholders regarding the accounts or auditor reports during the session.

Shelter Pharma reported receiving positive feedback from Dr. C.M. Patel regarding three of its human healthcare products. The endorsement highlights the effectiveness and natural composition of the company's offerings, signaling growing acceptance among medical professionals.

The specific products praised include Lemonade Barley Water, Alkaliser syrup, and Joemega capsules. Dr. Patel shared these reviews via social media platforms, emphasizing the unique formulation and benefits in supporting children's overall growth and development. This public validation serves to enhance brand credibility and consumer trust within the company's healthcare segment.

Regulatory disclosure details

The company filed an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to disclose this development. The filing clarifies that the event is ongoing and continuous in nature, rather than a one-time occurrence. Shelter Pharma stated that it is sharing this information on a voluntary basis and does not expect any immediate material impact on its financials.

Strategic implications

The positive reception aligns with the company's focus on quality, safety, and reliability across its portfolio. By securing endorsements from recognized medical figures, Shelter Pharma aims to strengthen its presence and credibility in the competitive healthcare industry. The management noted that this feedback reaffirms the confidence reposed by healthcare professionals and consumers in their ethical business practices.

No quantitative financial data was disclosed alongside this announcement, limiting the analysis to qualitative brand reinforcement within the specified product lines.